Role of Adjuvant Treatment in Resected Pancreatic Ductal Adenocarcinoma
- MeSH Terms
- pancreatic neoplasms, carcinoma, pancreatic ductal, pancreatic ductal adenocarcinoma, pancreatic cancer, pancreas cancer, pancreas adenocarcinoma, adjuvant treatment, cancer adjuvant therapy, adjuvant therapy, resected pancreatic ductal adenocarcinoma, chemotherapy, adjuvant, antineoplastic agents, drug therapy, pancreas adenocarcinoma, pancreas carcinoma, pancreas tumor, adjuvant chemotherapy, adjuvant chemoradiotherapy
- Guideline Contact
- Roxanne Cosby; [email protected]
- Keywords
- pancreatic ductal adenocarcinoma, pancreatic cancer, adjuvant treatment, antineoplastic agents, adjuvant chemoradiotherapy
- Date for Review
- In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
- Publication Date
- 2022-06-20
- Date of Last Evidence Search
- 2021-11-25
- Methods Applied
- Systematic review-based, Externally reviewed, Evidence quality assessment, Patient/survivors/caregivers participation
- Publication Scope
- Guidelines
- treatment
- Countries of Application
- Canada
- Guideline Publication Status
- Published
- Languages
- English
- Authors
- PEBC (Program in evidenced-based care)
- Publication Year
- 2022